

Australian Precision Oncology Symposium 2025 (APOS 25) Summary Report



Cancer
meets its match

Event Summary



376
Attendees

In person and virtual, including Australian oncology professionals— oncologists, researchers, pathologists, and members of the life science and advocacy sectors.

23
Speakers

2 international speakers along with experts from around Australia.

APOS 25 focused on 'The Coming of Age of Precision Oncology' – reflecting the shift from theoretical promise to transformative clinical practice. The event brought together renowned international and local experts, offering a broad spectrum of perspectives on the latest advancements shaping the future of cancer care.

Program highlights included cutting-edge therapeutics, technological innovations, real-world data insights, and clinical impact. A live molecular oncology board rounded out the agenda, showcasing how precision oncology is being applied in real time to guide patient care.



Program Details

Friday, 7 March 2025

Session 1: Molecular therapeutics - Chaired by Dr Greg Gaughran

- 1:00 - 1:10pm** **Welcome and opening remarks**
Professor David Thomas, Chief of Science and Strategy, Omico
Welcome to country
Aunty Maxine Ryan, La Perouse Aboriginal Community
- 1:10 - 1:45pm** **MoST CIRCUIT - Immunotherapy succeeds in rare cancers**
Associate Professor Oliver Klein - 25min talk, 10min Q&A
- 1:45 - 2:05pm** **Results from the phase 1 part of the PYNACLE study assessing Rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation**
Dr Amy Body - 15min talk, 5min Q&A
- 2:05 - 2:25pm** **Clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation**
Dr Timothy Humphries - 15min talk, 5min Q&A
- 2:25 - 2:35pm** **MAT2A inhibitor trial in progress**
Dr Malaka Ameratunga - 7min talk, 3min Q&A
- 2:35 - 2:45pm** **Prevalence of MTAP deletion in Australia**
Dr Sam Harris - 7min talk, 3min Q&A

Session 2: Transforming technologies - Chaired by Prof. David Thomas

- 3:15 - 3:50pm** **Precision diagnostics: Multi-cancer early detection using ctDNA in the SYMPLIFY study**
Professor Mark Middleton - 25min talk, 10min Q&A
- 3:50 - 4:10pm** **Beyond Ovarian Cancer: Navigating the Challenges of Expanding HRD Testing**
Associate Professor Anna Brown - 15min talk, 5min Q&A
- 4:10 - 4:30pm** **Omico's Screening Strategy for ADC/bispecific Ab Targets**
Dr Maya Kansara - 15min talk, 5min Q&A
- 4:30 - 4:50pm** **Targeting telomere replication stress to treat ALT cancers**
Professor Hilda Pickett - 15min talk, 5min Q&A
- 4:50 - 5:20pm** **Panel: Emerging technologies in precision oncology - Chaired by Prof. David Thomas**
Prof Mark Middleton, A/Prof Anna Brown, Prof Hilda Pickett, Dr Maya Kansara - 30 min talk & Q&A

Saturday, 8 March 2025

Session 3: Cancer in the young and survivorship - Chaired by A/Prof. Mandy Ballinger

- 9:00 - 9:10am** **Opening remarks**
A/Professor Mandy Ballinger, Head of Cohorts, Omico
Honouring International Women's Day
Christine Cockburn, CEO, Rare Cancers Australia
- 9:10 - 9:45am** **Long-term adverse health outcomes in survivors of adolescent and young adult cancer**
Dr Raoul Reulen - 25min talk, 10min Q&A
- 9:45 - 10:05am** **Novel omics strategies for personalised risk management**
Professor David Thomas - 15min talk, 5min Q&A
- 10:05 - 10:25am** **Germline cancer predisposition in the young**
Dr Milita Zaheed - 15min talk, 5min Q&A
- 10:25 - 10:45am** **Panel: The changing face of germline cancer genetics**
Professor David Thomas, Dr Milita Zaheed, A/Prof Kathy Tucker, Dr Noemi Fuentes-Bolanos - 20min talk & Q&A

Session 4: From research to clinical impact - Chaired by Dr Min Li Huang

- 11:10 - 11:40am** **The evolving role of comprehensive genomic profiling in tumour diagnosis and classification.**
A/Prof Catherine Mitchell - 20min talk, 10min Q&A
- 11:40 - 12:00pm** **Detecting what's missing: Sensitivity trade-offs in liquid biopsies versus prior NGS panels and comparator CGP tissue biopsies**
Dr Greg Gaughran - 15min talk, 5min Q&A
- 12:00 - 12:20pm** **Pharmacogenetics and public health impact**
Dr Kosar Hooshmand - 15min talk, 5min Q&A
- 12:20 - 12:40pm** **Impact of matched treatment - looking beyond survival**
Dr Ronald Chan - 15min talk, 5min Q&A

Session 5: Live molecular oncology board - Chaired by Prof. David Thomas

- 1:30 - 2:30pm** **Individual cases from molecular pathology to treatment recommendations**
Prof Hui Gan, Prof Damien Kee, Dr John Grady, Dr Min Li Huang, Dr Milita Zaheed, Dr Subo Thavaneswaran - 60min talk & Q&A
- 2:30 - 2:45pm** **Close**
Professor David Thomas

Thank you to our sponsors



Silver Sponsors:



9


Sponsors

We sincerely appreciate the generous support and active involvement of our event sponsors who played a key role in the success of APOS 25.

Bronze Sponsors:



Posters: Clinical Trials in Australia



Posters - a new feature in APOS 25

Highlighting clinical trials available in Australia, expanding access to innovative treatment options for people with challenging cancers.

[Click here](#)

to view individual posters that were displayed at APOS 25.

Thank you!

We thank our industry colleagues for their poster contributions: Alterome Therapeutics, Amgen, Bayer, BeiGene, Boehringer Ingelheim, Fore Biotherapeutics, Hummingbird Bioscience, Jiangsu Hengrui Pharmaceuticals, PMV Pharmaceuticals, Prelude Therapeutics, MSD, Servier, Merck Serono and NHMRC CTC.



Social Media Impact

11,429+ Impressions

On content posted on Omico social media channels.

**Number does not include impressions from shared content.*

22 Mentions & Reposts

Mentions & Reposts

Of APOS 25 on social media channels not including Omico's account.

Armella Zadoorian · 3rd+
Inside Sales Specialist at Bio-Rad Laboratories
2w · 🌐

With the Federal Government's recent \$143.4 million investment in precision medicine research, **Omico's #APOS25** was a timely and exciting opportunity to explore the latest advancements in precision oncology.

It was likewise a privilege to catch up with **David Thomas**, my Garvan UROP supervisor, and **Ronald Chan**, my USYD PhD mentor, among the many brilliant oncologists, researchers and business development professionals driving innovations in this space.

Thank you to **Omico** for organising such a fantastic symposium. The future of personalised care is in excellent hands!

29 reactions

Monash Partners Comprehensive Cancer Consortium · 495 followers
2w · 🌐

MPCCC is proud to be a sponsor of **#APOS 2025!**

For years, we've partnered with **Omico** to advance precision oncology, and we're excited to continue this impactful collaboration.

This year's Australian Precision Oncology Symposium (APOS) 2025 marks a pivotal moment as precision oncology transitions from theory to transformative practice. Bringing together oncologists, researchers, pathologists, life science experts, and advocates, APOS 25 will shape the future of cancer care in Australia.

👉 We look forward to engaging with leading minds and driving innovation in precision oncology for years to come.

#APOS25 #PrecisionOncology #CancerResearch #Collaboration #MPCCC

6 reactions

Omico
3,736 followers
2w · Edited · 🌐

#APOS 25 (Australia Precision Oncology Symposium) has kicked off! Thank you to our delegates joining us today—both in person and virtually!

To keep up with the day, you can view the full program and speaker list here: <https://lnkd.in/gn4y2btv>

👉 We thank our APOS 25 sponsors for their support:
Silver sponsors: **AstraZeneca GSK**
Bronze sponsors: **Monash Partners Comprehensive Cancer Consortium Australia & New Zealand Illumina Bayer Servier Pharmaceuticals Biotherapeutics Merck Group**

#APOS25Sponsor #Omico #APOS25 #AustralianPrecisionOncologySymposium2025 #PrecisionOncology #CancerMeetsItsMatch #ComprehensiveGenomicProfiling #ClinicalTrials #TreatmentMatching

62 reactions

Kerith-Rae Dias, PhD · 3rd+
Business Development Manager, Decode Science
2w · 🌐

Nothing short of remarkable attending the Australian Precision Oncology Symposium (APOS) at **UNSW**.

Moving theory to transformative practice took centre stage and revolved around the central theme of unmet need, defined by patients with rare cancers, patients in regional/rural areas, or even unique genomic profiles, reflected on by **Ian Black**, CEO, **Omico**

A palpable feeling of being at an inflection point having Professor **David Thomas**, Chief Science and Strategy Officer at Omico and Director of the Centre of Molecular Oncology, UNSW, create an environment where the community of leading Australian oncologists challenged each other and drove innovation in real time.

With the Federal Government's investment of \$30.8M to advance Omico's **#PROSPeCT** program, I am excited for the advancements in genomics, targeted therapies, personalized treatment plans and new pathways to market, with a patient-centred approach, to come to life.

#PrecisionOncology #ComprehensiveGenomicProfiling #ClinicalTrials #BiotechStartups

Michail Charakidis · 2nd
MD, FRACP, MClintRes, SCE (Med Onc), ESMO Certification
2w · ⋮

Thank you Omico for the wonderful event and thank you even more for giving us the opportunity to showcase our experience in the recruitment of Aboriginal Peoples to the CaSP study! Your support is very motivational and your work inspiring.

Like · 1 | Reply · 3 Replies

Omico · Author
3,736 followers
2w · ⋮

Michail Charakidis, great to have your contribution to this meeting. We can't do what we do without the collaboration with you and others in the medical and research community. Thanks for all that you do 🙏. We're delighted that you found **#APOS25** of value.

Like · Reply · 24 Impressions

Lucille Sebastian · 2nd
National Clinical Network Program Manager
2w · ⋮

Michail Charakidis Thank you and your team for working so hard for all people with cancer in your region. We are very happy to support you in equal measure.

Like · 1 | Reply

Michail Charakidis · 2nd
MD, FRACP, MClintRes, SCE (Med Onc), ESMO Certification
1w · ⋮

Lucille Sebastian thank you ever so much!!

Like · Reply

Collapse replies

Dr Erin Evans · 2nd
Experienced CEO | Entrepreneur- XR technology | Facilitator | Speaker | ...
2w · ⋮

Well done on a hugely successful APOS meeting **Omico** team!

Like · 1 | Reply · 1 Reply

Omico · Author
3,736 followers
2w · ⋮

Dr Erin Evans - thank you, it's lovely to have your feedback. It had a great feel about it!

Like · Reply · 60 Impressions

Event Communication

Effective use of online tools

Emails were essential for encouraging participation and communicating program details with delegates, resulting in high engagement.

44.24%

Open rate

Open rate of APOS 25 emails achieved an open rate of 44.24%, eclipsing the industry standard of 34.7%.

14.15%

Click rate

Click rate of APOS 25 emails were at a 14.15% high surpassing the industry standard of 1.75%.



Delegate Feedback

The following results were obtained post-event via online and in person surveys out of a total of 59 responses – Average scores out of 10.

How interesting/educational did you find the content of the Symposium:

9.1

APOS 25 has provided you with insights you can share with your colleagues:

8.9

How likely would it be that you attend a similar educational meeting if offered in the future:

9.4

Program Format:

8.9

Event Venue/Broadcast:

9

Event Organisation:

9.4

Feedback

The following examples were obtained from online and in person surveys, from a total of 59 responses.

“

It's a very insightful conference.
The format and sessions are all very interesting.

Excellent and very welcoming - Thank you!

Thank you and look forward to APOS 2026.

Excellent! Extremely well organised.
Networking dinner - Fantastic atmosphere.

I found a great number of the presentations highly valuable. Whilst I do not have a clinical and research background, I found a number of presenters did an excellent job of conveying content in an easy to understand manner.

Organised well, remote/online access was excellent - one of the best.
enjoyed all the sessions.

I felt the symposium was professionally run, with the schedule running largely to time, with very relevant topics and engaging speakers. It was a wonderful networking opportunity, and the collection of remarkable individuals showcasing their work provided so much hope for the future for those in the room.

Organised well, remote/online access was excellent - one of the best. enjoyed all the sessions.
could consider having a primer/educational session for non-biological scientists

”

APOS 25 Image Gallery



Australian Precision Oncology Symposium 2025 (APOS 25)



APOS 25 is now available online.

Click here

to explore videos of presentations, and posters,
from the event.

For any further information on APOS 25, please
contact Marketing Manager Fidan Rasimoglou via email
at f.rasimoglou@omico.org.au.

Cancer
meets its match



Omico.

Australian
Precision Oncology
Symposium